Acrivon Therapeutics, Inc.

Historical 13F Holders

Symbol
ACRV
CUSIP
004890109
All holders as of
Q2 2026
Type
Equity
Class
COMMON STOCK
Reported Value, Excluding Options
Total Filings

13D/G Filers

Investors who own more than 5% of a class must file a Schedule 13D or 13G. Every filing for 004890109 since 12/18/2024, newest first.

Filer % of Class Filed
Sands Capital Life Sciences Pulse Fund II, L.P. 13G/A Amendment 4
5.3% 8/13/2026
Event 6/30/2026
Citadel Advisors LLC 13G/A Amendment 1
0% 5/15/2026
Event 3/31/2026
RA Capital Management, L.P. 13D/A Amendment 4
28.8% 4/23/2026
Event 4/22/2026
RA Capital Management, L.P. 13D/A Amendment 3
21.6% 3/23/2026
Event 3/19/2026
Citadel Advisors LLC 13G
5.5% 11/21/2025
Event 11/14/2025
Citadel Advisors LLC 13G/A Amendment 4
4.9% 11/14/2025
Event 9/30/2025
Sands Capital Life Sciences Pulse Fund II, L.P. 13G/A Amendment 3
6.8% 8/13/2025
Event 6/30/2025
Perceptive Advisors LLC 13G/A Amendment 5
0% 6/4/2025
Event 6/2/2025
Citadel Advisors LLC 13G/A Amendment 3
6.0% 5/15/2025
Event 3/31/2025
Perceptive Advisors LLC 13G/A Amendment 4
9.9% 5/1/2025
Event 4/29/2025

13F Holders by Quarter

Period Filings Shares, Excl. Options Value, Excl. Options
2026 Q2 46 21.4 M $38.1 M
2026 Q1 44 16.2 M $22.6 M
2025 Q4 48 18.6 M $44.9 M
2025 Q3 49 17.5 M $32.7 M
2025 Q2 55 17.8 M $21.2 M
2025 Q1 64 22.5 M $45.7 M
2024 Q4 65 23.7 M $142 M
2024 Q3 58 23.1 M $162 M
2024 Q2 59 23.5 M $136 M
2024 Q1 52 15.3 M $109 M
2023 Q4 45 15.4 M $74.8 M
2023 Q3 46 15.1 M $144 M
2023 Q2 41 15.1 M $196 M
2023 Q1 41 15.2 M $191 M
2022 Q4 19 15.0 M $170 M